Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.

@article{Davies2006PharmacodynamicSO,
  title={Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer.},
  author={Angela M. Davies and Cheryl Ho and Primo N. Lara and Philip C. Mack and Paul H. Gumerlock and David R. Gandara},
  journal={Clinical lung cancer},
  year={2006},
  volume={7 6},
  pages={385-8}
}
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) given concurrently with chemotherapy do not improve patient outcomes compared with chemotherapy alone in advanced-stage non-small-cell lung cancer (NSCLC). One potential explanation for this lack of benefit is a negative interaction or antagonism between chemotherapy and EGFR TKIs when delivered concomitantly. Support for this line of reasoning is provided by preclinical data demonstrating that EGFR TKIs induce primarily… CONTINUE READING
54 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…